Evidence map›Paper›PMID 28346399›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2017

Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis.

Peter J Wermuth, Kellan R Carney, Fabian A Mendoza, Sonsoles Piera-Velazquez, Sergio A Jimenez

Open access · bronzeAbstract read
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Transforming growth factor-β in tissue fibrosis.The Journal of experimental medicine · 2020
    Review
  14. Abrogation of transforming growth factor-β-induced tissue fibrosis in mice with a global genetic deletion of Nox4.Laboratory investigation; a journal of technical methods and pathology · 2019
    Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Peter J WermuthJefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0002-0242-7265
Kellan R CarneyJefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Fabian A MendozaRheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Sonsoles Piera-VelazquezJefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Sergio A JimenezJefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Thomas Jefferson University · US

Funding

BIOCHEMICAL AND VASCULAR ALTERATIONS IN SCLERODERMAR01AR019616 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI JIMENEZ, SERGIO A · 1986 to 2010
$3.2M
NIAMS NIH HHS R01 AR019616
6 · The paper itself

Abstract

In this study, we tested the hypothesis that constitutive endothelial cell-specific activation of TGF-β signaling induces tissue fibrosis and vasculopathy resembling the characteristic fibrotic and vascular alterations of systemic sclerosis. Transgenic mice with inducible expression of a constitutively active TGF-β receptor I specifically in endothelial cells were generated by intercrossing mice harboring a constitutively active TGF-β receptor I with a mouse strain containing the endothelial cell-specific Cdh5 gene promoter directing the tamoxifen-inducible expression of the Cre-ER

Indexed as

AnimalsEndothelial CellsFemaleFibrosisHydroxyprolineImmunohistochemistryLungMaleMiceMice, TransgenicMicroscopy, ConfocalOrgan SpecificitySignal TransductionTamoxifenTransforming Growth Factor betaHydroxyprolineTamoxifenTransforming Growth Factor beta

Identifiers

PMID28346399
PMCPMC6530474
OpenAlexW2599991662

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.